1. Search Result
Search Result
Results for "

genotype 1b replicons

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6798
    Myriocin
    10+ Cited Publications

    Thermozymocidin; ISP-I

    HCV Antibiotic Infection
    Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection .
    Myriocin
  • HY-15602
    Ledipasvir
    30+ Cited Publications

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir
  • HY-10466
    Daclatasvir
    Maximum Cited Publications
    47 Publications Verification

    BMS-790052; EBP 883

    HCV Infection
    Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir
  • HY-13998
    Dasabuvir
    10+ Cited Publications

    ABT-333

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir
  • HY-10465
    Daclatasvir dihydrochloride
    Maximum Cited Publications
    47 Publications Verification

    BMS-790052 dihydrochloride; EBP 883 dihydrochloride

    HCV Infection
    Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir dihydrochloride
  • HY-109035
    Inarigivir soproxil
    1 Publications Verification

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
    Inarigivir soproxil
  • HY-13465
    VCH-916
    1 Publications Verification

    HCV Infection
    VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase with sub-micromolar IC50 values versus genotype 1a and 1b replicons. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .
    VCH-916
  • HY-10118
    Filibuvir
    4 Publications Verification

    HCV DNA/RNA Synthesis Infection
    Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
    Filibuvir
  • HY-15602C

    GS-5885 hydrochloride

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir hydrochloride
  • HY-10465R

    BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)

    Reference Standards HCV Infection
    Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir dihydrochloride (Standard)
  • HY-U00213

    R803

    HCV Infection
    Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).
    Furaprofen
  • HY-131905S

    Isotope-Labeled Compounds HCV Protease HCV Infection Inflammation/Immunology Cancer
    BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
    BMS-986144
  • HY-15602S

    GS-5885-d6

    HCV SARS-CoV Infection
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir-d6
  • HY-102030

    HCV Infection
    BMS-961955 is an orally active inhibitor of HCV NS5B polymerase. BMS-961955 exhibits potent inhibitory activity against HCV genotype 1 (GT-1a/1b) replicons with EC50s of 4.3 nM and 7.9 nM, respectively. BMS-961955 can be used for the study of HCV infection .
    BMS-961955
  • HY-13998A

    ABT-333 sodium

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir sodium
  • HY-136267

    HCV Infection
    HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
    HCV-IN-30
  • HY-19921

    HCV Infection
    JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
    JTK-853
  • HY-10466S

    BMS-790052-d6; EBP 883-d6

    Isotope-Labeled Compounds HCV Infection
    Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir-d6
  • HY-10466S2

    BMS-790052-d16; EBP 883-d16

    Isotope-Labeled Compounds HCV Infection
    Daclatasvir-d16 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir-d16
  • HY-15602S1

    GS-5885-d16

    Isotope-Labeled Compounds HCV SARS-CoV Infection
    Ledipasvir-d16 (GS-5885-d16) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir-d16
  • HY-10466R

    BMS-790052 (Standard); EBP 883 (Standard)

    Reference Standards HCV Infection
    Daclatasvir (Standard) is the analytical standard of Daclatasvir. This product is intended for research and analytical applications. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir (Standard)
  • HY-13998R

    ABT-333 (Standard)

    Reference Standards HCV DNA/RNA Synthesis Infection
    Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir (Standard)
  • HY-125182

    Cyclophilin HCV Infection
    SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .
    SMCypI C31
  • HY-N6798R

    Thermozymocidin (Standard); ISP-I (Standard)

    Reference Standards HCV Antibiotic Infection
    Myriocin (Standard) is the analytical standard of Myriocin. This product is intended for research and analytical applications. Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].
    Myriocin (Standard)
  • HY-10466S1

    BMS-790052-13C2,d6; EBP 883-13C2,d6

    Isotope-Labeled Compounds HCV Infection
    Daclatasvir- 13C2,d6 (BMS-790052- 13C2,d6) is 13C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
    Daclatasvir-13C2,d6
  • HY-108029

    ACH-2684 sodium; Neceprevir sodium

    HCV HCV Protease Infection
    Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .
    Deldeprevir sodium
  • HY-182691

    HCV Infection
    Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against HCV genotype 1a and 1b replicons and reduces HCV RNA levels. Amphihevir can be used in the research of chronic hepatitis C .
    Amphihevir
  • HY-123536

    A-831

    PI4K HCV Infection
    AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC50 values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively .
    AZD2836
  • HY-182679

    HCV Infection
    L0909 is an HCV inhibitor with an EC50 of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection .
    L0909
  • HY-117802

    DNA/RNA Synthesis HCV HCV Protease Infection
    CID-50930756 is an HCV NS3 helicase inhibitor with an IC50 of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c .
    CID-50930756

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: